Login to Your Account


Next step in AML study advances ganetespib to phase III extension

By Randy Osborne
Staff Writer

Tuesday, July 22, 2014

With its lead cancer drug unpartnered and a new CEO yet to be chosen, Synta Pharmaceuticals Corp. is advancing the phase II/III AML LI-1 trial to test the chemosensitizing mettle of the heat-shock protein 90 inhibitor ganetespib.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription